Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 110

Similar articles for PubMed (Select 23836088)

1.

Opioid induced bowel disease: a twenty-first century physicians' dilemma. Considering pathophysiology and treatment strategies.

Sharma A, Jamal MM.

Curr Gastroenterol Rep. 2013 Jul;15(7):334. doi: 10.1007/s11894-013-0334-4. Review.

PMID:
23836088
2.

Opioid-induced bowel dysfunction: pathophysiology and management.

Brock C, Olesen SS, Olesen AE, Frøkjaer JB, Andresen T, Drewes AM.

Drugs. 2012 Oct 1;72(14):1847-65. doi: 10.2165/11634970-000000000-00000. Review.

PMID:
22950533
3.

A randomized, placebo-controlled phase 3 trial (Study SB-767905/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain.

Irving G, Pénzes J, Ramjattan B, Cousins M, Rauck R, Spierings EL, Kleoudis CS, Snidow JW, Pierce A, Wurzelmann J, Mortensen ER.

J Pain. 2011 Feb;12(2):175-84. doi: 10.1016/j.jpain.2010.06.013.

PMID:
21292168
4.

Incidence, prevalence, and management of opioid bowel dysfunction.

Pappagallo M.

Am J Surg. 2001 Nov;182(5A Suppl):11S-18S. Review.

PMID:
11755892
5.

Mu-opioid antagonists for opioid-induced bowel dysfunction.

McNicol ED, Boyce D, Schumann R, Carr DB.

Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006332. doi: 10.1002/14651858.CD006332.pub2. Review.

PMID:
18425947
6.

Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain.

Webster L, Jansen JP, Peppin J, Lasko B, Irving G, Morlion B, Snidow J, Pierce A, Mortensen E, Kleoudis C, Carter E.

Pain. 2008 Jul 15;137(2):428-40. doi: 10.1016/j.pain.2007.11.008. Epub 2007 Dec 31.

PMID:
18164818
7.

The role of opioid receptor antagonists in the treatment of opioid-induced constipation: a review.

Leppert W.

Adv Ther. 2010 Oct;27(10):714-30. doi: 10.1007/s12325-010-0063-0. Epub 2010 Aug 26. Review.

PMID:
20799006
8.

Opioid-induced bowel dysfunction.

Ketwaroo GA, Cheng V, Lembo A.

Curr Gastroenterol Rep. 2013 Sep;15(9):344. doi: 10.1007/s11894-013-0344-2. Review.

PMID:
23900996
9.

A review of the potential role of methylnaltrexone in opioid bowel dysfunction.

Foss JF.

Am J Surg. 2001 Nov;182(5A Suppl):19S-26S. Review.

PMID:
11755893
10.

The impact of opioid analgesics on the gastrointestinal tract function and the current management possibilities.

Leppert W.

Contemp Oncol (Pozn). 2012;16(2):125-31. doi: 10.5114/wo.2012.28792. Epub 2012 May 29.

11.

Methylnaltrexone bromide: new drug for the treatment of opioid-induced bowel dysfunction.

Baker DE.

Rev Gastroenterol Disord. 2009 Summer;9(3):E84-93. Review.

PMID:
19898269
12.

Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness.

Chamberlain BH, Cross K, Winston JL, Thomas J, Wang W, Su C, Israel RJ.

J Pain Symptom Manage. 2009 Nov;38(5):683-90. doi: 10.1016/j.jpainsymman.2009.02.234. Epub 2009 Aug 26.

PMID:
19713070
13.

New approaches to the treatment of opioid-induced constipation.

Holzer P.

Eur Rev Med Pharmacol Sci. 2008 Aug;12 Suppl 1:119-27. Review.

14.

Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction.

Leppert W.

Drug Des Devel Ther. 2015 Apr 16;9:2215-31. doi: 10.2147/DDDT.S32684. eCollection 2015. Review.

15.

Lubiprostone for the treatment of opioid-induced bowel dysfunction.

Wong BS, Camilleri M.

Expert Opin Pharmacother. 2011 Apr;12(6):983-90. doi: 10.1517/14656566.2011.566559. Epub 2011 Mar 9. Review.

PMID:
21385112
16.

A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain.

Jansen JP, Lorch D, Langan J, Lasko B, Hermanns K, Kleoudis CS, Snidow JW, Pierce A, Wurzelmann J, Mortensen ER.

J Pain. 2011 Feb;12(2):185-93. doi: 10.1016/j.jpain.2010.06.012.

PMID:
21292169
17.

Methylnaltrexone: treatment for opioid-induced constipation.

Licup N, Baumrucker SJ.

Am J Hosp Palliat Care. 2011 Feb;28(1):59-61. doi: 10.1177/1049909110373507. Epub 2010 Aug 27. Review.

PMID:
20801917
18.

[Opioid-induced bowel dysfunction: a literature analysis on pathophysiology and treatment].

Osterbrink J, Haas U.

Wien Med Wochenschr. 2008;158(21-22):621-6. doi: 10.1007/s10354-008-0589-9. Review. German.

PMID:
19052708
19.

Management of opioid-induced bowel dysfunction in cancer patients.

Tamayo AC, Diaz-Zuluaga PA.

Support Care Cancer. 2004 Sep;12(9):613-8. Review.

PMID:
15221581
20.

Methylnaltrexone: a novel approach for the management of opioid-induced constipation in patients with advanced illness.

Diego L, Atayee R, Helmons P, von Gunten CF.

Expert Rev Gastroenterol Hepatol. 2009 Oct;3(5):473-85. doi: 10.1586/egh.09.42. Review.

PMID:
19817669
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk